Outcome of Elderly Nasopharyngeal Carcinoma  Patients: A Single Center Study

Hamit Başaran; Mustafa Cengiz; Gözde Yazıcı; Yurday Özdemir; Nilda Süslü; İbrahim H. Güllü; Gökhan Özyigit

doi:10.5152/eurjther.2019.19079

Authors

Hamit Başaran Department of Radiation Oncology, Tekirdağ State Hospital, Tekirdağ https://orcid.org/0000-0002-2122-8720
Mustafa Cengiz Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara https://orcid.org/0000-0003-3692-8532
Gözde Yazıcı Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara https://orcid.org/0000-0002-7430-6729
Yurday Özdemir Department of Radiation Oncology, Başkent University Adana Dr. Turgut Noyan Research and Treatment Center, Adana https://orcid.org/0000-0002-2218-2074
Nilda Süslü Department of Otorhinolaryngology, Hacettepe University School of Medicine, Ankara https://orcid.org/0000-0001-9901-3044
İbrahim H. Güllü Department of Medical Oncology, Hacettepe University School of Medicine, Ankara https://orcid.org/0000-0002-6000-6311
Gökhan Özyigit Department of Radiation Oncology, Hacettepe University School of Medicine, Ankara https://orcid.org/0000-0002-7497-4348

DOI:

https://doi.org/10.5152/eurjther.2019.19079

Keywords:

Chemoradiotherapy, elderly, nasopharyngeal carcinoma, survival

Abstract

Objective: This study aimed to assess the efficiency of radiotherapy and evaluate its outcomes for elderly (>65 years) patients who have undergone treatment for nasopharyngeal carcinoma (NPC).
Methods: Forty-five (male, 35; female, 10) elderly patients with a diagnosis of undifferentiated NPC who were treated at our institution between 1994 and 2012 were retrospectively evaluated. The primary endpoint was the relationship between the patients’ characteristics and overall survival (OS); progression-free survival (PFS), locoregional progression-free survival (LR-PFS), and toxicity analysis were the secondary endpoints.
Results: The patients had a median age of 74.2 years. At a median follow-up period of 64 months, the median OS, PFS, and LR-PFS were 45 (95% confidence interval [CI]: 5.887-84.113), 34 (95% CI: 0.0-70.504), and 45 (95% CI: 20.092-69908) months, respectively. The 2-, 3-, and 5-year OS rates were 61.5%, 53.1%, and 50.0%, respectively, and the 2-, 3-, and 5-year PFS rates were 57.6%, 46.8%, and 43.7%, respectively. Patients with T stage (T3-T4 vs.T1–T2) or N stage (N0–1 vs. N2) had significantly shorter OS (p<0.05), PFS (p<0.05), and LR-PFS (p<0.05) outcomes, respectively, which were also confirmed using a multivariate analysis (p<0.05).
Conclusion: Our results demonstrated that the established prognostic factors, including T and N stages, were important prognostic indicators of NPC in elderly patients.

Metrics

Metrics Loading ...

References

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-54.

Wang HY, Chang YL, To KF, Hwang JSG, Mai HQ, FengYF, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer 2016; 35: 41.

Chan AT. Nasopharyngeal carcinoma. Ann Oncol 2010; 21: i308-12.

Wei KR, Xu Y, Liu J, Zhang WJ, Liang ZH. Histopathological classification of nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2011; 12: 1141-7.

He J, Wu P, Tang Y, Liu S, Xie C, Luo S, et al. Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis. Oncotarget 2017; 8: 39782-94.

Lin JC, Jan JS, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-7.

Sze HC, Ng WT, Chan OSH, Shum TCY, Chan LLK, Lee AWM, et al. Radical radiotherapy for nasopharengeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 2012; 48: 162-7.

Zhang L, Zhao C, Hong MH, Liu Q, Zhang Y, Guo Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 2010; 10: 558.

Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.

Wolden SL, Chen WC, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.

Xiao WW, Han F, Chen CY, Huang Y, Zhaoet C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009; 74: 1070-6.

Xie SH, Yu ITS, Tse LA, Wai-kong Mang O, Yue L. Sex diference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: suggestion of a potential protective role of oestrogen. Eur J Cancer 2013; 49: 150-5.

Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase 2 trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-9.

Chen L, Hu CS, Chen XZ, Hu GK, Cheng ZB, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13: 163-71. 15. 15. Xiao G, Cao Y, Qiu X, Wang W, Wang Y, et al. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 2013; 13: 226.

Surveillance, Epidemiology, and End Results: SEER Cancer Statistics Review, 1975-2010. Available From: URL: http:// seer.cancer.gov/csr/1975_2010.

Kang MK, Heo D, Ahn YC, Moon SH, Wu HG, Heoet DS, et al. Role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat 2015; 47: 871‐8.

Jin YN, Zhang WJ, Cai XY, Li MS, Lawrence WR, Wang SY, et al. The characteristics and survival outcomes in patients aged 70 years and older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy. Cancer Res Treat 2019; 51: 34-42.